Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.

Cancer Res Commun · 2022 · PMC10010343 · PMID 36923309

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an overall trendno p-value reported

There was an overall trend of a small increase after priming at week 9 which requires confirmation in a larger cohort ( Fig. 5 ).

also in 2,064 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.